TABLE 4.

Summary of treatment‐emergent adverse events (TEAEs) in patients ≥50 years of age (safety population)

	Eptinezumab 100 mg (n = 132)	Eptinezumab 300 mg (n = 127)	Placebo (n = 126)
Patients with any TEAE, n (%)	62 (46.6%)	68 (53.5%)	66 (52.4%)
Mild	26 (19.5%)	24 (18.9%)	25 (19.8%)
Moderate	32 (24.1%)	42 (33.1%)	36 (28.6%)
Severe	4 (3.0%)	2 (1.6%)	4 (3.2%)
Life‐threatening	0	0	1 (0.8%)
Most common TEAEs (≥ 2% of total patients), n (%)
Nasopharyngitis	7 (5.3%)	11 (8.7%)	6 (4.8%)
Upper respiratory tract infection	6 (4.5%)	10 (7.9%)	8 (6.3%)
Urinary tract infection	4 (3.0%)	7 (5.5%)	3 (2.4%)
Dizziness	4 (3.0%)	5 (3.9%)	3 (2.4%)
Fatigue	5 (3.8%)	4 (3.1%)	2 (1.6%)
Sinusitis	2 (1.5%)	3 (2.4%)	5 (4.0%)
Back pain	3 (2.3%)	3 (2.4%)	3 (2.4%)
Patients with any TEAE leading to treatment discontinuation, n (%)	2 (1.5%)	1 (0.8%)	4 (3.2%)
Patients with any TEAE related to study drug, n (%)	14 (10.5%)	18 (14.2%)	13 (10.3%)
Patients with ≥1 serious adverse event, n (%)	2 (1.5%)	1 (0.8%)	3 (2.4%)
Syncope	1 (0.8%)	0	1 (0.8%)
Apnea	0	0	1 (0.8%)
Breast cancer	0	1 (0.8%)	0
Cellulitis	0	0	1 (0.8%)
Chronic obstructive pulmonary disease	0	0	1 (0.8%)
Depression suicidal	1 (0.8%)	0	0
Gastric ulcer	1 (0.8%)	0	0
Hematemesis	1 (0.8%)	0	0
Migraine	0	0	1 (0.8%)
Tibia fracture	1 (0.8%)	0	0